Metabolic
Semaglutide
GLP-1 receptor agonist · Metabolic research
A long-acting analog of human glucagon-like peptide-1 with extensive published literature across glycemic, weight, and cardiovascular research endpoints.
For laboratory research use only. Not for human or animal consumption, not a drug, food, cosmetic, or supplement. By adding to cart, the researcher affirms compliance with all applicable regulations.
Vial size
Research price
$169
SKU ABL-SEM-2
Ships cold-chain · Lot ABL-SEM-2604 · Checkout secured by Waave
Specifications
Semaglutide is a long-acting analog of human GLP-1 in which position 8 is modified to resist DPP-4 degradation and a C18 fatty diacid linker enables reversible albumin binding for extended half-life. The molecule is approved as Ozempic®, Wegovy®, and Rybelsus® for glycemic and weight endpoints.
A large body of clinical and preclinical literature has investigated Semaglutide's actions at the GLP-1 receptor across islet cell function, gastric emptying, central appetite regulation, and cardiovascular outcomes.
Supplied exclusively as a laboratory reference standard for research investigating the GLP-1 axis. Not supplied for therapeutic use.
Related research tools